Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.

ABSTRACT:

Objective

Interest continues to grow regarding the therapeutic potential for umbilical cord blood therapies to modulate autoimmune disease. We conducted an open-label phase I study using autologous umbilical cord blood infusion to ameliorate type 1 diabetes.

Research design and methods

Fifteen patients diagnosed with type 1 diabetes and for whom autologous umbilical cord blood was stored underwent a single intravenous infusion of autologous cells and completed 1 year of postinfusion follow-up. Intensive insulin regimens were used to optimize glycemic control. Metabolic and immunologic assessments were performed before infusion and at established time periods thereafter.

Results

Median (interquartile range [IQR]) age at infusion was 5.25 (3.1-7.3) years, with a median

SUBMITTER: Haller MJ 

PROVIDER: S-EPMC2768209 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature